# Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

> **NCT05049343** · PHASE1 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** SAGE-904
- **DRUG:** Placebo
- **DRUG:** Ketamine

## Key facts

- **NCT ID:** NCT05049343
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-21
- **Primary completion:** 2021-11-20
- **Final completion:** 2021-12-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049343, "Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05049343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*